Jane Street’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.7K | Buy |
365,600
+47,800
| +15% | +$11.2K | ﹤0.01% | 11211 |
|
|
2026
Q1 | $78.5K | Buy |
317,800
+232,200
| +271% | +$92.4K | ﹤0.01% | 10756 |
|
|
2025
Q4 | $36K | Buy |
85,600
+37,400
| +78% | +$19.8K | ﹤0.01% | 10595 |
|
|
2025
Q3 | $32.5K | Sell |
48,200
-40,300
| -46% | -$21.7K | ﹤0.01% | 10441 |
|
|
2025
Q2 | $47.9K | Buy |
88,500
+34,700
| +64% | +$20.6K | ﹤0.01% | 9185 |
|
|
2025
Q1 | $35.3K | Sell |
53,800
-23,800
| -31% | -$25.2K | ﹤0.01% | 9067 |
|
|
2024
Q4 | $79.2K | Buy |
77,600
+62,400
| +411% | +$114K | ﹤0.01% | 8848 |
|
|
2024
Q3 | $13.2K | Buy |
+15,200
| New | +$11.1K | ﹤0.01% | 9330 |
|
|
2023
Q1 | – | Sell |
-21,800
| Closed | -$68.5K | – | 9827 |
|
|
2022
Q4 | $68.5K | Sell |
21,800
-12,600
| -37% | -$48.9K | ﹤0.01% | 8260 |
|
|
2022
Q3 | $169K | Buy |
34,400
+12,400
| +56% | +$63.7K | ﹤0.01% | 8316 |
|
|
2022
Q2 | $91K | Buy |
22,000
+3,000
| +16% | +$13K | ﹤0.01% | 8690 |
|
|
2022
Q1 | $110K | Sell |
19,000
-74,100
| -80% | -$441K | ﹤0.01% | 9409 |
|
|
2021
Q4 | $698K | Buy |
93,100
+38,400
| +70% | +$334K | ﹤0.01% | 6636 |
|
|
2021
Q3 | $493K | Sell |
54,700
-41,900
| -43% | -$414K | ﹤0.01% | 7300 |
|
|
2021
Q2 | $1.16M | Sell |
96,600
-57,600
| -37% | -$652K | ﹤0.01% | 5524 |
|
|
2021
Q1 | $1.93M | Sell |
154,200
-134,600
| -47% | -$1.81M | ﹤0.01% | 4088 |
|
|
2020
Q4 | $4.51M | Buy |
288,800
+211,300
| +273% | +$2.48M | ﹤0.01% | 2266 |
|
|
2020
Q3 | $732K | Sell |
77,500
-78,800
| -50% | -$852K | ﹤0.01% | 4596 |
|
|
2020
Q2 | $1.4M | Buy |
156,300
+137,500
| +731% | +$1.28M | ﹤0.01% | 3580 |
|
|
2020
Q1 | $120K | Buy |
+18,800
| New | +$139K | ﹤0.01% | 4876 |
|
|
2019
Q1 | – | Sell |
-15,100
| Closed | -$173K | – | 5564 |
|
|
2018
Q4 | $173K | Sell |
15,100
-4,800
| -24% | -$59.6K | ﹤0.01% | 4523 |
|
|
2018
Q3 | $337K | Buy |
+19,900
| New | +$302K | ﹤0.01% | 4071 |
|
|
2018
Q2 | – | Sell |
-25,100
| Closed | -$477K | – | 5546 |
|
|
2018
Q1 | $477K | Buy |
25,100
+8,500
| +51% | +$182K | ﹤0.01% | 3510 |
|
|
2017
Q4 | $272K | Buy |
+16,600
| New | +$247K | ﹤0.01% | 3876 |
|
|
2016
Q1 | – | Sell |
-17,800
| Closed | -$163K | – | 4588 |
|
|
2015
Q4 | $163K | Buy |
+17,800
| New | +$137K | ﹤0.01% | 3684 |
|
Other funds holding SGMO
NAMI
AIM
FTUS
HIG
Jane Street's SGMO Position: Q1 2026 in Review
Jane Street sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 2,918,127 shares — an estimated $1.16M sold.
Jane Street first reported a position in SGMO in Q2 2013 and held it in 34 quarters. The position peaked at $2.89M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.
- Jane Street reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 2,918,127 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $1.16M.
- Jane Street first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 34 quarters.
- Jane Street's SANGAMO THERAPEUTICS INC position peaked at $2.89M in Q4 2020.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.